Urticaria is characterized by sudden appearance of wheals and/or angioedema.
The intensity of the pruritus varies but may be severe enough to disrupt sleep, work or school.
It is classified acute if the urticaria has been present for <6 weeks and chronic if >6 weeks. A specific cause is more likely to be identified in acute cases.
It can be triggered by immunological or nonimmunological mechanism.
New drug applications approved by US FDA as of 01 - 15 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Rupatadine effectively relieves pruritus in patients with chronic spontaneous urticaria and is well tolerated without serious or clinically significant adverse effects, according to the results of a phase III trial.
Omalizumab appears to effectively reduce the signs and symptoms of chronic spontaneous urticaria (CSU) in Japanese and Korean patients who remain symptomatic despite the use of nonsedating second-generation H1 antihistamines (H1AH), according to the results of POLARIS study.
Men who undergo flexible cystoscopy, particularly with a longer dwell time, may benefit from intraurethral lidocaine as it provides significant pain reduction, suggest the results of a meta-analysis. Evidence is lacking for other tested interventions.
While douching is not associated with the risk of ovarian cancer, the combination of talc and commercially available douches contributes to a modest increase in the risk of epithelial ovarian cancer beyond that conferred by talc use alone, as shown in a recent study.